Corcym

Executive Summary

Corcym is a private, UK-based medical device company specializing in innovative cardiac surgery solutions, particularly in the structural heart market. Founded in 2020 and headquartered in London, the company offers a portfolio of heart valve prostheses and repair devices, including the Perceval sutureless aortic valve, Carbomedics and Bicarbons mechanical valves, and HAART devices for aortic root reconstruction. Corcym’s mission is to partner with cardiac surgeons to improve patient outcomes through advanced precision-engineered technologies. The Perceval valve, its flagship product, is designed to reduce cross-clamp and cardiopulmonary bypass times, potentially expanding access to minimally invasive aortic valve replacement. Corcym operates in a competitive landscape dominated by Edwards Lifesciences, Medtronic, and Abbott, but its focus on sutureless technology and comprehensive valve portfolio positions it as a niche player with growth potential. The company benefits from increasing demand for less invasive surgical options and an aging population with structural heart disease. As a private entity, Corcym’s financial details are limited, but its product lineup and clinical data suggest a steady commercial presence. Upcoming catalysts include pivotal trial readouts and potential regulatory expansions that could drive adoption. Given the lack of public financials and competitive pressures, the conviction score is moderate.

Upcoming Catalysts (preview)

• Q3 2026Pivotal Trial Results for Perceval Valve in Bicuspid Aortic Stenosis70% success
• Q1 2027FDA Approval for Perceval Valve Expanded Indication60% success
• TBDStrategic Partnership for Distribution in Asia-Pacific50% success